I

Instituto Cardiovascular de León S.C. | León, Mexico

Research site

(Unclaimed)

Location

Paseo de Los Quetzales 136 int 201, León, Guanajuato, Mexico

Site insights

Top conditions

Top treatments

Orforglipron

Retatrutide

LY3502970

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 3 total trials

Locations recently updated

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling

Chronic Kidney Disease

Overweight

Drug: Orforglipron

Drug: Insulin Glargine

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

Locations recently updated

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling

Overweight and Obesity

Drug: Retatrutide

Drug: Placebo

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms